TabsDetailsBasic DetailsDate: Thursday, November 26, 2020Type: PublicationDescription: To better understand the occurrence of uterine bleeding (UB) events requiring intervention in women treated with oral anticoagulants (OAs), we examined the incidence of UB events in the Food and Drug Administration’s (FDA) Sentinel System. Read More Materials: Am. J. Obstet. Gynecol. 2020 Nov 26. doi.org/10.1016/j.ajog.2020.11.034Additional InformationRelated Assessment(s): Incidence of Severe Uterine Bleed Following Novel Oral Anticoagulants Use: A Descriptive AnalysisContributorsAuthor(s): Abby Anderson, Audrey Gassman, Laura Hou, Ting-Ying Huang, Efe Eworuke, David Moeny, Hui-Lee WongCorresponding Author: Abby Anderson; Division of Urology, Obstetrics, and Gynecology, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USAEmail: abby.anderson@fda.hhs.gov
